28511906|t|Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin -based caps and o-phenylenediamine -based zinc binding groups
28511906|a|As a hot topic of epigenetic studies, histone deacetylases (HDACs) are related to lots of diseases, especially cancer. Further researches indicated that different HDAC isoforms played various roles in a wide range of tumor types. Herein a novel series of HDAC inhibitors with isatin -based caps and o-phenylenediamine -based zinc binding groups have been designed and synthesized through scaffold hopping strategy. Among these compounds, the most potent compound 9n exhibited similar if not better HDAC inhibition and antiproliferative activities against multiple tumor cell lines compared with the positive control entinostat (MS-275). Additionally, compared with MS-275 (IC50 values for HDAC1, 2 and 3 were 0.163, 0.396 and 0.605µM, respectively), compound 9n with IC50 values of 0.032, 0.256 and 0.311µM for HDAC1, 2 and 3 respectively, showed a moderate HDAC1 selectivity.
28511906	0	6	Design	T052	C1707689
28511906	8	17	synthesis	T052	C1883254
28511906	22	41	anti-tumor activity	T044	C1148560
28511906	42	47	study	T062	C2603343
28511906	57	87	histone deacetylase inhibitors	T116,T121,T126	C1512474
28511906	99	105	isatin	T109,T121,T130	C0022115
28511906	113	117	caps	T104	C1254350
28511906	122	140	o-phenylenediamine	T109,T131	C0043796
28511906	148	167	zinc binding groups	T104	C1254350
28511906	186	204	epigenetic studies	T091	C1655731
28511906	206	226	histone deacetylases	T116,T126	C0019643
28511906	228	233	HDACs	T116,T126	C0019643
28511906	258	266	diseases	T047	C0012634
28511906	279	285	cancer	T191	C0027651
28511906	295	305	researches	T062	C0035168
28511906	321	330	different	T080	C1705242
28511906	331	344	HDAC isoforms	T116,T126	C0019643
28511906	360	365	roles	T077	C1705810
28511906	385	396	tumor types	T033	C4263544
28511906	413	419	series	T081	C0205549
28511906	423	438	HDAC inhibitors	T116,T121,T126	C1512474
28511906	444	450	isatin	T109,T121,T130	C0022115
28511906	458	462	caps	T104	C1254350
28511906	467	485	o-phenylenediamine	T109,T131	C0043796
28511906	493	512	zinc binding groups	T104	C1254350
28511906	523	531	designed	T052	C1707689
28511906	536	547	synthesized	T052	C1883254
28511906	548	555	through	T169	C0332273
28511906	556	581	scaffold hopping strategy	T059	C0022885
28511906	595	604	compounds	T103	C1706082
28511906	622	633	compound 9n	T103	C1706082
28511906	659	665	better	T080	C0332272
28511906	666	670	HDAC	T116,T126	C0019643
28511906	671	681	inhibition	T039	C1524081
28511906	686	714	antiproliferative activities	T044	C1148560
28511906	723	731	multiple	T081	C0439064
28511906	732	748	tumor cell lines	T025	C0085983
28511906	749	757	compared	T052	C1707455
28511906	767	783	positive control	T077	C1883676
28511906	784	794	entinostat	T109,T121	C2743752
28511906	796	802	MS-275	T109,T121	C1510480
28511906	819	827	compared	T052	C1707455
28511906	833	839	MS-275	T109,T121	C1510480
28511906	841	845	IC50	T081	C0600495
28511906	846	852	values	T081	C1522609
28511906	857	862	HDAC1	T116,T126	C2718309
28511906	864	865	2	T116,T126	C0768528
28511906	870	871	3	T116,T126	C1098658
28511906	918	929	compound 9n	T103	C1706082
28511906	935	939	IC50	T081	C0600495
28511906	940	946	values	T081	C1522609
28511906	979	984	HDAC1	T116,T126	C2718309
28511906	986	987	2	T116,T126	C0768528
28511906	992	993	3	T116,T126	C1098658
28511906	1026	1031	HDAC1	T116,T126	C2718309
28511906	1032	1043	selectivity	T080	C0205556